Agios Pharmaceuticals (AGIO) to Release Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of ($1.74) per share and revenue of $9.46 million for the quarter.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The business had revenue of $8.73 million for the quarter, compared to analysts' expectations of $9.86 million. On average, analysts expect Agios Pharmaceuticals to post $-7 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO traded up $0.35 on Friday, hitting $40.00. The stock had a trading volume of 529,138 shares, compared to its average volume of 668,393. Agios Pharmaceuticals has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of 3.56 and a beta of 0.73. The firm has a 50-day moving average of $34.98 and a 200-day moving average of $32.50.

Analyst Ratings Changes

AGIO has been the topic of several recent analyst reports. Scotiabank lowered their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Finally, Bank of America lowered their price objective on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $57.33.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider James William Burns sold 2,799 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $93,878.46. Following the transaction, the insider directly owned 28,650 shares of the company's stock, valued at $960,921. The trade was a 8.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Cecilia Jones sold 1,780 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $59,701.20. Following the completion of the transaction, the chief financial officer directly owned 30,049 shares in the company, valued at $1,007,843.46. This trade represents a 5.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,363 shares of company stock worth $1,619,654 over the last 90 days. Insiders own 4.30% of the company's stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC bought a new position in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $40,000. Acadian Asset Management LLC purchased a new position in Agios Pharmaceuticals during the 1st quarter valued at about $133,000. Woodline Partners LP purchased a new position in Agios Pharmaceuticals in the first quarter worth about $597,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Agios Pharmaceuticals by 7.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company's stock worth $1,274,000 after buying an additional 2,920 shares during the last quarter. Finally, AQR Capital Management LLC increased its holdings in Agios Pharmaceuticals by 66.8% in the 1st quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company's stock worth $1,498,000 after buying an additional 20,625 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.